Medtronic PLC

Medtronic PLC(MDT)の株式分析

$90.650

-0.580 (-0.64%)終値時点

Loading chart…
High
91.120
Open
90.750
VWAP
90.60
Vol
12.63M
Mkt Cap
101.72B
Low
90.040
Amount
1.14B
EV/EBITDA, TTM
12.07

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

AI analysis of Medtronic PLC (MDT)

buy

Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.

Analyst Ratings (23)

+23.29% upside
Hold
11 Buy
12 Hold
0 Sell
Current: 90.65
安値
102.00
平均
111.76
高値
120.00

TD Cowen

2026-08-28

目標株価

$110

Buy

Needham

2026-08-27

目標株価

$114

Buy

UBS

2026-07-28

目標株価

$100

Buy

Evercore ISI

2026-07-06

目標株価

$105

Outperform

BofA

2026-06-12

目標株価

$95

Buy

バリュエーション指標

The current forward P/E ratio for Medtronic PLC (MDT) is 15.11, compared to its 5-year average forward P/E of 16.24.

Forward P/E

Fair
5Y Average P/E
16.24
Current P/E
15.11
割高
18.18
割安
14.30

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
13.79
Current EV/EBITDA
12.07
割高
15.33
割安
12.25

Forward P/S

Undervalued
5Y Average P/S
3.49
Current P/S
2.90
割高
4.05
割安
2.93

Alphio AI Price Scenarios for MDT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MDT

$89.49

シナリオ価格

B

Base

Base · 50%MDT

$72.02

シナリオ価格

B

Bear

Bear · 25%MDT

$70.55

シナリオ価格

Whales holding MDT

I

Integral Health Asset Management, LLC

+ HoldingMDT

+16.87%

3M Return

B

Burgundy Asset Management Ltd.

+ HoldingMDT

+11.83%

3M Return

B

Bellevue Asset Management AG

+ HoldingMDT

+11.29%

3M Return

E

Equity Investment Corporation

+ HoldingMDT

+10.15%

3M Return

C

Crawford Investment Counsel, Inc.

+ HoldingMDT

+9.72%

3M Return

C

Chilton Investment Company, Inc.

+ HoldingMDT

+9.07%

3M Return

イベントタイムライン

2026-09-01 (ET)

07:00:00

Medtronic Announces Strategic Partnership with Cornerstone Robotics

07:00:00

Medtronic Q1 Revenue of $9.8B Beats Expectations

07:00:00

Medtronic Invests Up to $80M in Pi-Cardia

07:00:00

FY27 Organic Revenue View Raised to 7.25%-7.75%

2026-08-26 (ET)

10:30:00

Canada Raises Tariffs on U.S. Steel and Aluminum to 50%

ニュース

MDT FAQ — answered by Alphio AI

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める